272-67-3

Usage

Uses

Used in Pharmaceutical Synthesis:
Thieno[3,2-b]pyridine is utilized as a key intermediate in the development of pharmaceutical drugs due to its ability to form diverse chemical structures. Its presence in drug molecules can contribute to enhanced biological activity and selectivity, making it an essential component in the creation of new therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Thieno[3,2-b]pyridine is employed as a structural element in the design of novel compounds with potential therapeutic applications. Its unique ring system allows for the exploration of new chemical space and the discovery of molecules with improved pharmacological profiles.
Used in Disease Treatment Research:
Thieno[3,2-b]pyridine and its derivatives have been studied for their potential applications in treating various diseases and disorders. Their biological activities, which can vary based on the specific structural modifications, make them promising candidates for further research and development in therapeutic interventions.
Used in Material Science:
Beyond its pharmaceutical applications, Thieno[3,2-b]pyridine also finds use in the development of new materials and chemical processes. Its chemical properties can be harnessed to create innovative materials with unique characteristics, contributing to advances in various industries.

InChI:InChI=1/C7H5NS/c1-2-7-6(8-4-1)3-5-9-7/h1-5H

Upstream product

• 69627-03-8 7-chlorothieno[3,2-b]pyridine 
• 1217903-01-9 3-[(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidenemethyl)amino]thiophene-2-carbaldehyde 
• 69627-02-7 thieno[3,2-b]pyridin-7-ol 

Downstream Products

• 26579-59-9 3-Nitrothieno<3,2-b>pyridin 
• 94191-19-2 2-hydroxymethylthieno<3,2-b>pyridine 
• 94191-15-8 2-bromothieno<3,2-b>pyridine 
• 94191-16-9 2,3-dibromothieno<3,2-b>pyridine 
• 94191-17-0 2-iodothieno<3,2-b>pyridine 
• 94191-12-5 3-bromothieno<3,2-b>pyridine 
• 94191-20-5 2-cyanothieno<3,2-b>pyridine 
• 116538-95-5 thieno[3,2-b]pyridine-6-carbonitrile 
• 69627-02-7 thieno[3,2-b]pyridin-7(4H)-one 
• 73010-06-7 2-Amino-thieno<3,2-b>pyridin 
• 104273-32-7 7-aminothieno<3,2-b>pyridine hydrate 
• 69627-03-8 7-chlorothieno[3,2-b]pyridine 
• 1402598-43-9 N-(phenyl(thieno[3,2-b]pyridin-2-yl)methyl)-3,4-dihydro-2H-1,5-benzodioxepine-7-sulfonamide 

Relevant academic research and scientific papers

2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 2-amino-N-(amino-oxo-aryl-λ6- sulfanylidene)acetamide compounds (referred to herein as ANASIA compounds) that, inter alia, inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase; to treat disorders that are ameliorated by the inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetase; to treat bacterial infections; etc.

Cyclisation reactions of some pyridazinylimidoylketenes

Flash vacuum pyrolysis (FVP) of aminopyridazinone derivatives of Meldrum's acid at 600 °C (0.02 Torr) results in generation of an imidoylketene intermediate followed by cyclisation. In the case of the 5-amino derivatives, the products are pyrido[2,3-d]pyridazines, whereas the 4-amino compounds lead to mixtures of pyrido[2,3-d]pyridazines and pyrrolo[3,2-c]pyridazines. The feasibility of the 1,5-sigmatropic shift of a chlorine atom, required for the formation of two of the pyrido[2,3-d]pyridazines, was supported by the corresponding reaction of a corresponding 2,6-dichloroaniline derivative. The feasibility of the decarboxylation mechanism required for the formation of the pyrrolo[3,2-c]pyridazines, was supported by related processes in the FVP reactions of model compounds and by DFT calculations.

IMIDAZOPYRIDAZINE COMPOUNDS

The present invention relates to novel substituted imidazo[1,2-b] pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.